search
Back to results

The Effect of a Patient Decision Aids for Breast Cancer Screening

Primary Purpose

Breast Cancer, Mammary Cancer, Breast Tumor

Status
Unknown status
Phase
Not Applicable
Locations
Chile
Study Type
Interventional
Intervention
Decision aid (DA) for breast cancer screening
Standarised information for breast cancer screening
Sponsored by
Pontificia Universidad Catolica de Chile
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Breast Cancer focused on measuring Breast Cancer, Decision aid, Decision making process, Mammography, Breast Cancer Screening

Eligibility Criteria

50 Years - 69 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women from 50 to 69 years old
  • Attend the primary care centres
  • Fluent in Spanish

Exclusion Criteria:

  • Women with a personal history of breast cancer
  • Have a current mammogram (as recommended by the Chilean Ministry of Health)
  • Not having the capacity to consent.

Sites / Locations

  • Alejandra MartínezRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Intervention group

Control group

Arm Description

The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records. The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?

The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system. The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records.

Outcomes

Primary Outcome Measures

Informed choice for breast cancer screening
An adapted and validated version of the informed choice questionnaire will be used: this is a five-item questionnaire to measure informed choice (Bravo P, Dois A, Fernández-González L, Hernández-Leal MJ, Villarroel L. [Validation of the Informed Choice instrument for Chilean women facing a mammography decision in primary care]. Aten Primaria. 2021 Mar;53(3):101943. doi: 10.1016/j.aprim.2020.08.005. Epub 2021 Feb 13. Spanish. PubMed ID: 33592532). Minimum value= 5 Maximum value= 25

Secondary Outcome Measures

Decisional conflict
Decisional conflict scale with 16 items that measure uncertainty in the decision making process. Minimum value= 16 Maximum value= 80
Depression, anxiety and stress
This will be measured with the DASS-21 Scale, a self-reported 21-item that captures depression, anxiety and stress during the last week. Minimum value= 21 Maximum value= 84
Satisfaction with the decision
This is a two-item self-reported satisfaction questionnaire related to breast cancer screening. Minimum value= 0 Maximum value= 1
Number of participants who undertake a mammography
This will be the number of women who decided to undertake the mammography. This outcome will be obtained from the clinical record of each participant six months after baseline questionnaires. Minimum value= 0 Maximum value= 1

Full Information

First Posted
June 7, 2021
Last Updated
August 3, 2022
Sponsor
Pontificia Universidad Catolica de Chile
Collaborators
Comisión Nacional de Investigación Científica y Tecnológica
search

1. Study Identification

Unique Protocol Identification Number
NCT04948983
Brief Title
The Effect of a Patient Decision Aids for Breast Cancer Screening
Official Title
Patient Decision Aids for Women Facing the Decision of Breast Cancer Screening in the Public Health Sector
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
October 31, 2022 (Anticipated)
Study Completion Date
October 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pontificia Universidad Catolica de Chile
Collaborators
Comisión Nacional de Investigación Científica y Tecnológica

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres. A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted.
Detailed Description
There is an alarming rise of breast cancer in developing countries, where early detection is rare and the late findings build up an important mortality rate. In Chile, the mortality rate is 15,5 per 100.000 women, where breast cancer is the first death caused by tumors. Governmental efforts had focused on increase an opportune detection and had offered universal and guaranteed access to breast cancer screening to women in at-risk age (50 to 59 years old). Still, about 30% of the women of at-risk age choose to not do the mammogram. Anxiety and lack of awareness are the principal reasons associated with the decision of rejecting or postponing the exam. Women would have trouble in making an informed decision about the breast cancer exam, resulting in possible negatives consequences for their wellbeing. Considering that the health-related decision-making process depends importantly on the personal balance of risk and benefits related to the decision, it is imperative to explore strategies that support women in the decision-making progress for breast cancer screening. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres; 4) A two-arm randomized control trial will be conducted with a total of 3,269 women aged 50 to 69 years old in ten primary care centres in Chile. The intervention group will access a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group will access a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups will complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate will be measure. Multiple lineal regression analysis will be conducted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Mammary Cancer, Breast Tumor, Mammary Tumor
Keywords
Breast Cancer, Decision aid, Decision making process, Mammography, Breast Cancer Screening

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The intervention group will access a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group will access a webpage, answers a set of questionnaires at baseline, and then receive standardised information given by the healthcare system. Both groups will complete the questionnaires two weeks later.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3269 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Active Comparator
Arm Description
The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records. The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system. The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records.
Intervention Type
Other
Intervention Name(s)
Decision aid (DA) for breast cancer screening
Intervention Description
The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
Intervention Type
Other
Intervention Name(s)
Standarised information for breast cancer screening
Intervention Description
Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
Primary Outcome Measure Information:
Title
Informed choice for breast cancer screening
Description
An adapted and validated version of the informed choice questionnaire will be used: this is a five-item questionnaire to measure informed choice (Bravo P, Dois A, Fernández-González L, Hernández-Leal MJ, Villarroel L. [Validation of the Informed Choice instrument for Chilean women facing a mammography decision in primary care]. Aten Primaria. 2021 Mar;53(3):101943. doi: 10.1016/j.aprim.2020.08.005. Epub 2021 Feb 13. Spanish. PubMed ID: 33592532). Minimum value= 5 Maximum value= 25
Time Frame
Change from baseline informed choice at two weeks
Secondary Outcome Measure Information:
Title
Decisional conflict
Description
Decisional conflict scale with 16 items that measure uncertainty in the decision making process. Minimum value= 16 Maximum value= 80
Time Frame
Change from baseline decisional conflict at two weeks
Title
Depression, anxiety and stress
Description
This will be measured with the DASS-21 Scale, a self-reported 21-item that captures depression, anxiety and stress during the last week. Minimum value= 21 Maximum value= 84
Time Frame
Change from baseline drepression, anxiety and stress at two weeks
Title
Satisfaction with the decision
Description
This is a two-item self-reported satisfaction questionnaire related to breast cancer screening. Minimum value= 0 Maximum value= 1
Time Frame
Change from baseline satisfaction with the decision at two weeks
Title
Number of participants who undertake a mammography
Description
This will be the number of women who decided to undertake the mammography. This outcome will be obtained from the clinical record of each participant six months after baseline questionnaires. Minimum value= 0 Maximum value= 1
Time Frame
At 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women from 50 to 69 years old Attend the primary care centres Fluent in Spanish Exclusion Criteria: Women with a personal history of breast cancer Have a current mammogram (as recommended by the Chilean Ministry of Health) Not having the capacity to consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paulina Bravo, PhD
Phone
(56-2) 2354 5838
Email
pbbravo@uc.cl
First Name & Middle Initial & Last Name or Official Title & Degree
Alejandra Martinez, MSc
Phone
+56940742491
Email
alejandra.martinez@uc.cl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paulina Bravo, PhD
Organizational Affiliation
Pontificia Universidad Catolica de Chile
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alejandra Martínez
City
Santiago
ZIP/Postal Code
sANTIAGO
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alejandra Martínez

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33592532
Citation
Bravo P, Dois A, Fernandez-Gonzalez L, Hernandez-Leal MJ, Villarroel L. [Validation of the Informed Choice instrument for Chilean women facing a mammography decision in primary care]. Aten Primaria. 2021 Mar;53(3):101943. doi: 10.1016/j.aprim.2020.08.005. Epub 2021 Feb 13. Spanish.
Results Reference
result

Learn more about this trial

The Effect of a Patient Decision Aids for Breast Cancer Screening

We'll reach out to this number within 24 hrs